Printer Friendly

Fauls to Manage Regulatory Affairs at JenaValve Technology.

M2 PHARMA-January 8, 2016-Fauls to Manage Regulatory Affairs at JenaValve Technology

(C)2016 M2 COMMUNICATIONS

- US-based heart-valve technology company JenaValve Technology, Inc. has appointed veteran medical device executive Janet M. Fauls as vice president of regulatory affairs, the company said.

Fauls, who has nearly 30 years of regulatory and clinical affairs experience, will be based at JenaValve's corporate headquarters in Irvine, California.

Most recently, Fauls served as vice president of global regulatory affairs for Endologix, Inc. in Irvine, California.

Prior to Endologix, Fauls held management positions of increasing responsibility in regulatory and clinical affairs positions at major global medical technology companies including Edwards Life Sciences, Cardiogenesis Corp. and Allergan, Inc. Fauls earned B.S. in Chemistry from the University of California at Santa Barbara.

JenaValve Technology, with operating locations in Irvine, California, Leeds, England and Munich, Germany, develops, manufactures and markets transcatheter aortic valve replacement systems to treat a broad spectrum of patients suffering from aortic valve disease.

The company's Transapical TAVR system, consisting of the JenaValve valve system plus Cathlete PLUS delivery system, has CE Mark approval for aortic valve stenosis and for the unique indication to treat patients suffering from aortic valve insufficiency.

JenaValve currently markets this product in Europe and other selected markets worldwide. JenaValve is backed by US, European and Asian investors.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1U9CA
Date:Jan 8, 2016
Words:227
Previous Article:Pursuit Vascular Touts Study Results for ClearGuard HD Antimicrobial Barrier Caps.
Next Article:ACell Launches Two Wound Management Devices.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters